Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2020-03-26 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于召开2019年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2019 Annual General Meeting (AGM) of 特一药业集团股份有限公司, including the meeting date, agenda items, voting procedures, and proxy forms. It contains no financial statements or detailed financial analysis but focuses on the logistics and agenda of the AGM. The document is not the annual report itself but a notification about the AGM and the matters to be discussed and voted on at the meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length is about 5309 characters, which is consistent with a detailed AGM notice rather than a full annual report or other filings.
2020-03-26 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding a change in accounting policy, specifically the adoption of a new accounting standard (Accounting Standard No. 14 - Revenue) effective from January 1, 2020. It includes details about the reason for the change, the impact on financial statements, and opinions from the board, independent directors, and supervisory board. The document is relatively short (2058 characters) and does not contain actual financial statements or detailed financial data. It is a formal announcement about a policy change rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-03-26 Chinese
募集资金管理制度（2020年3月）
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the management, use, supervision, and regulatory compliance related to the company's raised funds. It extensively references laws and regulations governing the use of raised capital, the establishment of special accounts for raised funds, usage restrictions, reporting, and auditing requirements. The content is a detailed internal policy or management system document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but rather governance and procedural rules for managing raised capital. This fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices, including capital management policies.
2020-03-26 Chinese
第四届董事会第十次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 4th Board of Directors of 特一药业集团股份有限公司. It includes approval of the 2019 Board work report, 2019 General Manager work report, 2019 financial statements, profit distribution plan, internal control self-evaluation report, audit firm reappointment, and other corporate governance matters. The document also mentions that these resolutions will be submitted to the shareholders' meeting for approval. The document is not the annual report itself but a board meeting resolution announcement related to the annual report and other governance matters. It does not contain the full annual report or financial statements but rather the board's decisions and approvals. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting resolutions and management reports approval.
2020-03-26 Chinese
2019年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2019年度内部控制自我评价报告' which translates to '2019 Annual Internal Control Self-Evaluation Report' for 特一药业集团股份有限公司. It discusses the company's internal control evaluation for the fiscal year ending December 31, 2019, including detailed descriptions of internal control scope, evaluation criteria, and conclusions about the effectiveness of financial and non-financial internal controls. The document is comprehensive, contains substantive content about internal control evaluation, and is not merely an announcement or certification. It is not a full annual report (10-K) but a specialized report focused on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR). Therefore, the document should be classified as an Audit Report / Information (AR). FY 2019
2020-03-26 Chinese
国信证券股份有限公司关于公司2019年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Guosen Securities regarding the 2019 annual fundraising funds deposit and usage situation of a company. It references regulatory rules related to securities issuance and listing, and includes detailed financial data about the amount raised, usage, investment projects, and compliance with regulations. It also includes an audit opinion from an accounting firm on the fundraising funds usage. The document is focused on the verification and audit of the use of raised funds, not a full annual report or earnings release. It is not a simple announcement or certification but a substantive report on fundraising funds usage and compliance. This fits the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific financial matters, excluding full annual reports. The document length (9258 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2019
2020-03-26 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.